Using advanced HDX-MS and native MS techniques can improve the identification of potentially successful biologic drugs and de-risk CMC and clinical designs.
Jennifer S. Chadwick
Advertisement
Jennifer S. Chadwick, PhD, is director of biologic development at BioAnalytix.
Articles by Jennifer S. Chadwick
Advertisement
Latest Updated Articles
Advertisement
Advertisement